1. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation 
A.K. Singh, D.W. Coyne, W. Shapiro, A.R. Rizkala 
Kidney International 
Volume 71, Issue 11, Pages (June 2007)
DOI: /sj.ki
Copyright © 2007 International Society of Nephrology Terms and Conditions

2. Figure 1
Likelihood of response to anemia treatment without i.v. iron. (a–f) Ability of (a) transferrin saturation, (b) serum ferritin, (c) reticulocyte hemoglobin content, (d) soluble transferrin receptor, (e) C-reactive protein, and (f) magnitude of epoetin dose increase to predict likelihood of a clinically significant hemoglobin response (≥2g/dl increase in hemoglobin) to anemia treatment without the use of iron. (f) Response appears to be primarily driven by the magnitude of epoetin dose increase (P<0.05).
Kidney International  , DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions

3. Figure 2
Likelihood of response to anemia treatment using i.v. iron. (a–f) Ability of (a) transferrin saturation, (b) serum ferritin, (c) reticulocyte hemoglobin content, (d) soluble transferrin receptor, (e) C-reactive protein, and (f) magnitude of epoetin dose increase to predict likelihood of a clinically significant hemoglobin response (≥2g/dl increase in hemoglobin) to 1g of i.v. iron (8 × 125mg ferric gluconate). (c) Reticulocyte hemoglobin content ≥31.2pg/cell and (e) C-reactive protein <14.1mg/l were associated with greater likelihood of response to i.v. iron (both P<0.05). However, the likelihood of response to anemia treatment with i.v. iron was always greater than without i.v. iron, regardless of any level of reticulocyte hemoglobin content, C-reactive protein, or any other analyte.
Kidney International  , DOI: ( /sj.ki )
Copyright © 2007 International Society of Nephrology Terms and Conditions